Bjørn Naume

13.0k citations

134 papers · 6.7k indexed · 1 hit paper · h-index 45

Oncology top 0.5%
Cancer Research top 0.2%
Molecular Biology top 2%
Pulmonary and Respiratory Medicine top 2%
Immunology top 5%

Co-authors: Elin Borgen Anne‐Lise Børresen‐Dale Terje Espevik Vessela N. Kristensen Gunnar Kvalheim Hege G. Russnes Gro Wiedswang Thérese Sørlie
Topics: Cancer Cells and Metastasis (43 papers)Breast Cancer Treatment Studies (39 papers)Cancer Genomics and Diagnostics (30 papers)
Cited by: Cancer Research Oncology Immunology
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Nature Medicine
Partner nations: Norway United States Sweden

In The Last Decade

Bjørn Naume

129 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Allele-specific copy number analysis of tumors

2010 635 citations Silje Nord, Ole Christian Lingjærde et al. profile →

Peers

Countries citing papers authored by Bjørn Naume

Since Specialization

Citations

This map shows the geographic impact of Bjørn Naume's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bjørn Naume with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bjørn Naume more than expected).

Fields of papers citing papers by Bjørn Naume

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bjørn Naume. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bjørn Naume. The network helps show where Bjørn Naume may publish in the future.

Co-authorship network of co-authors of Bjørn Naume

This figure shows the co-authorship network connecting the top 25 collaborators of Bjørn Naume. A scholar is included among the top collaborators of Bjørn Naume based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bjørn Naume. Bjørn Naume is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis 2025 ·Communications Medicine ·(unknown),Xavier Tekpli,Ole Christian Lingjærde,Hege G. Russnes,Johan Vallon‐Christersson,Elin Borgen,Jon Lømo,(unknown),(unknown),Vessela N. Kristensen,Bjørn Naume,Jon Amund Kyte	0
2	Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown),(unknown),(unknown),Bjørnar Gilje,(unknown),Andrea Gombos,Ragnhild Sørum Falk,Randi R. Mathiesen,Lars Julsrud,Øystein Garred,Hege G. Russnes,(unknown),Sudhir Kumar Chauhan,Ole Christian Lingjærde,(unknown),Bjørn Naume,Jon Amund Kyte	8
3	Late effects after breast cancer treatment 2023 ·Tidsskrift for Den norske legeforening ·(unknown),(unknown),Harald Engan,Cecilie E. Kiserud,Bjørn Naume,Mette Brekke,Kristin V. Reinertsen	2
4	Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER‐positive breast cancer 2020 ·International Journal of Cancer ·(unknown),Tonje G. Lien,Xavier Tekpli,Laxmi Silwal‐Pandit,Elin Borgen,Øystein Garred,Helle Kristine Skjerven,Ellen Schlichting,Steinar Lundgren,Erik Wist,Bjørn Naume,Vessela N. Kristensen,Anne‐Lise Børresen‐Dale,Ole Christian Lingjærde,Olav Engebraaten	14
5	Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015–2016 2020 ·BMC Cancer ·Yngvar Nilssen,Odd Terje Brustugun,Morten Eriksen,Erik Skaaheim Haug,Bjørn Naume,Bjørn Møller	15
6	Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients 2019 ·Annals of Oncology ·Mads H. Haugen,Ole Christian Lingjærde,Oslo Garred,Ingrid Hedenfalk,Niklas Loman,Gordon B. Mills,Anne‐Lise Børresen‐Dale,Bjørn Naume,Gunhild M. Mælandsmo,Olav Engebråten	0
7	Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma 2017 ·Scientific Reports ·(unknown),Anshuman Panda,Surendra Kumar,Michael Seiler,(unknown),(unknown),Yao Ming,Grethe I.G. Alnæs,Deborah Toppmeyer,Margit Riis,Bjørn Naume,Anne‐Lise Børresen‐Dale,Vessela N. Kristensen,Shridar Ganesan,Gyan Bhanot	32
8	Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases 2017 ·Annals of Surgical Oncology ·(unknown),Cathrine Brunborg,Anne Waage,Harald Hugenschmidt,Anne Renolen,(unknown),Bjørn Atle Bjørnbeth,Elin Borgen,Bjørn Naume,Kristoffer W. Brudvik,Gro Wiedswang	18
9	Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4) 2017 ·Tumor Biology ·(unknown),Arne Westgaard,Elisabeth Paus,(unknown),(unknown),Bjørn Naume,Trine Bjøro	7
10	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial 2016 ·JNCI Journal of the National Cancer Institute ·Isabelle Gingras,Eileen Holmes,Evandro de Azambuja,David H. Nguyen,Miguel Izquierdo,Jo Anne Zujewski,Moshe Inbar,Bjørn Naume,Gianluca Tomasello,Julie R. Gralow,Antonio C. Wolff,Lyndsay N. Harris,Michael Gnant,Alvaro Moreno‐Aspitia,Martine Piccart,Hatem A. Azim	19
11	The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer 2015 ·PLoS ONE ·Laxmi Silwal‐Pandit,Hege G. Russnes,Elin Borgen,(unknown),Hans Kristian Moen Vollan,Ellen Schlichting,Rolf Kåresen,Bjørn Naume,Anne‐Lise Børresen‐Dale,Marianne Farnebo,Anita Langerød	17
12	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients 2014 ·Clinical Cancer Research ·Kristine Kleivi Sahlberg,Giulia Bottai,Bjørn Naume,Barbara Burwinkel,George A. Călin,Anne‐Lise Børresen‐Dale,Libero Santarpia	186
13	Genome-wide DNA methylation profiles in progression to in situand invasive carcinoma of the breast with impact on gene transcription and prognosis 2014 ·Genome biology ·Thomas Fleischer,Arnoldo Frigessi,Kevin C. Johnson,Hege Edvardsen,Nizar Touleimat,Jovana Klajic,Margit Riis,Vilde Drageset Haakensen,Fredrik Wärnberg,Bjørn Naume,Åslaug Helland,A.L. Børresen-Dale,Jörg Tost,Brock C. Christensen,Vessela N. Kristensen	139
14	18F-FDG PET : Changes in uptake as a method to assess radium-223 dichloride (Ra-223) response in bone metastases of breast cancer patients with bone-dominant disease 2013 ·Open Repository and Bibliography (University of Liège) ·Patrick Flamen,Robert Coleman,Bjørn Naume,Guy Jérusalem,(unknown),Anne-Kirsti Aksnes,Martine Piccart	1
15	Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study 2012 ·BMC Cancer ·Marit Synnestvedt,Elin Borgen,Erik Wist,Gro Wiedswang,(unknown),Terje Risberg,Christian Kersten,Ingvil Mjaaland,(unknown),Cecilie Bendigtsen Schirmer,Jahn M. Nesland,Bjørn Naume	18
16	Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis 2011 ·Clinical Cancer Research ·Wolfgang Janni,Florian D. Vogl,Gro Wiedswang,Marit Synnestvedt,Tanja Fehm,Julia Jückstöck,Elin Borgen,Brigitte Rack,Stephan Braun,Harald Sommer,Erich Solomayer,Klaus Pantel,Jahn M. Nesland,Klaus Friese,Bjørn Naume	192
17	A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide 2009 ·Clinical Cancer Research ·Sharon A. Glynn,Brenda J. Boersma,Tiffany M. Howe,Hege Edvardsen,Stephanie Geisler,Julie E. Goodman,Lisa A. Ridnour,Per Eystein Lønning,Anne‐Lise Børresen‐Dale,Bjørn Naume,Vessela N. Kristensen,Stephen J. Chanock,David A. Wink,Stefan Ambs	38
18	Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer 2007 ·Molecular Oncology ·Bjørn Naume,Xi Zhao,Marit Synnestvedt,Elin Borgen,Hege G. Russnes,Ole Christian Lingjærde,(unknown),Gro Wiedswang,Gunnar Kvalheim,Rolf Kåresen,Jahn M. Nesland,Anne‐Lise Børresen‐Dale,Thérese Sørlie	113
19	Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes 2007 ·Breast Cancer Research ·Silje Nord,Fredrik Johansen,Grethe I.G. Alnæs,Bjørn Naume,Anne‐Lise Børresen‐Dale,Vessela N. Kristensen	35
20	Immunomagnetic Techniques for the Enrichment and Detection of Isolated Breast Carcinoma Cells in Bone Marrow and Peripheral Blood 1997 ·Journal of Hematotherapy ·Bjørn Naume,Elin Borgen,Klaus Beiske,(unknown),(unknown),Anne Renolen,Sissel Trachsel,(unknown),Steinar Funderud,Gunnar Kvalheim	98

About Bjørn Naume

Bjørn Naume is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 134 papers that have together received 6.7k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (43 papers), Breast Cancer Treatment Studies (39 papers) and Cancer Genomics and Diagnostics (30 papers). The work is most often cited by research in Cancer Research (3.1k citations), Oncology (3.4k citations) and Immunology (862 citations). Bjørn Naume has collaborated with scholars based in Norway, United States and Sweden. Frequent co-authors include Elin Borgen, Anne‐Lise Børresen‐Dale, Terje Espevik, Vessela N. Kristensen, Gunnar Kvalheim, Hege G. Russnes, Gro Wiedswang, Thérese Sørlie, Rolf Kåresen and Silje Nord. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact